Loading…

Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors : A cohort study of 11,575 patients with coronary artery disease

The purpose of this study was to investigate the significance of the possible negative interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors. Several provocative reports have recently suggested that aspirin is unsafe in patients with heart failure and has negative interactio...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 1999-06, Vol.33 (7), p.1920-1925
Main Authors: LEOR, J, REICHER-REISS, H, GOLDBOURT, U, BOYKO, V, GOTTLIEB, S, BATTLER, A, BEHAR, S
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1925
container_issue 7
container_start_page 1920
container_title Journal of the American College of Cardiology
container_volume 33
creator LEOR, J
REICHER-REISS, H
GOLDBOURT, U
BOYKO, V
GOTTLIEB, S
BATTLER, A
BEHAR, S
description The purpose of this study was to investigate the significance of the possible negative interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors. Several provocative reports have recently suggested that aspirin is unsafe in patients with heart failure and has negative interaction with ACE inhibitors that might attenuate their beneficial effects upon survival. We analyzed mortality data of 11,575 patients with coronary artery disease screened for the Bezafibrate Infarction Prevention trial. A total of 1,247 patients (11%) were treated with ACE inhibitors. Of them, 618 patients (50%) used aspirin. Five-year mortality was lower among patients on ACE inhibitors and aspirin than patients on ACE inhibitors without aspirin (19% vs. 27%; p < 0.001). After adjusting for confounders, treatment with aspirin and ACE inhibitors remained associated with lower mortality risk than using ACE inhibitors only (relative risk [RR] = 0.71; 95% confidence interval [CI] = 0.56 to 0.91). Subgroup analysis of 464 patients with congestive heart failure treated with ACE inhibitors revealed 221 patients (48%) on aspirin and 243 patients not on aspirin. Although clinical characteristics and therapy were similar, patients taking aspirin experienced lower mortality than patients who did not (24% vs. 34%; p = 0.001). After adjustment, treatment with aspirin was still associated with lower mortality (RR = 0.70; 95% CI = 0.49 to 0.99). Among coronary artery disease patients with and without heart failure who are treated with ACE inhibitors, the use of aspirin was associated with lower mortality than treatment without aspirin. Our findings contradict the claim that aspirin attenuates the beneficial effect of ACE inhibitors and supports its use in patients with coronary artery disease treated with ACE inhibitors.
doi_str_mv 10.1016/S0735-1097(99)00129-1
format article
fullrecord <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_10362194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10362194</sourcerecordid><originalsourceid>FETCH-LOGICAL-h271t-1583a8d0569697139f92106d4c0bcb48c571654488f54b58f1e55040573c19363</originalsourceid><addsrcrecordid>eNpFkM1KAzEUhYMotv48gpKFCwVHcyfJJHFXin9QcKGuSyaT6UQ6mZKkyvgkPq6DVrs6cPnux-EgdALkCggU189EUJ4BUeJcqQtCIFcZ7KAxcC4zypXYReN_ZIQOYnwjhBQS1D4aAaFFDoqN0dckrlxwHmtf4bYLSS9d6vFwWOnkrE8Rp2B1shX-cKkZsIXrkvXR-cx0_t2G5PwCW__Zt3Z4a1zpUhcivsETbLpmMOKY1lWPuxoDXHLBt-Yfo-lC53XosQ7JDlG5aHW0R2iv1stojzd5iF7vbl-mD9ns6f5xOpllTS4gZcAl1bIivFCFEkBVrXIgRcUMKU3JpOECCs6YlDVnJZc1WM4JI1xQA4oW9BCd_npX67K11XwVXDu0mf9NNABnG0BHo5d10N64uOUkEXnO6DfSzXdh</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors : A cohort study of 11,575 patients with coronary artery disease</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><creator>LEOR, J ; REICHER-REISS, H ; GOLDBOURT, U ; BOYKO, V ; GOTTLIEB, S ; BATTLER, A ; BEHAR, S</creator><creatorcontrib>LEOR, J ; REICHER-REISS, H ; GOLDBOURT, U ; BOYKO, V ; GOTTLIEB, S ; BATTLER, A ; BEHAR, S</creatorcontrib><description>The purpose of this study was to investigate the significance of the possible negative interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors. Several provocative reports have recently suggested that aspirin is unsafe in patients with heart failure and has negative interaction with ACE inhibitors that might attenuate their beneficial effects upon survival. We analyzed mortality data of 11,575 patients with coronary artery disease screened for the Bezafibrate Infarction Prevention trial. A total of 1,247 patients (11%) were treated with ACE inhibitors. Of them, 618 patients (50%) used aspirin. Five-year mortality was lower among patients on ACE inhibitors and aspirin than patients on ACE inhibitors without aspirin (19% vs. 27%; p &lt; 0.001). After adjusting for confounders, treatment with aspirin and ACE inhibitors remained associated with lower mortality risk than using ACE inhibitors only (relative risk [RR] = 0.71; 95% confidence interval [CI] = 0.56 to 0.91). Subgroup analysis of 464 patients with congestive heart failure treated with ACE inhibitors revealed 221 patients (48%) on aspirin and 243 patients not on aspirin. Although clinical characteristics and therapy were similar, patients taking aspirin experienced lower mortality than patients who did not (24% vs. 34%; p = 0.001). After adjustment, treatment with aspirin was still associated with lower mortality (RR = 0.70; 95% CI = 0.49 to 0.99). Among coronary artery disease patients with and without heart failure who are treated with ACE inhibitors, the use of aspirin was associated with lower mortality than treatment without aspirin. Our findings contradict the claim that aspirin attenuates the beneficial effect of ACE inhibitors and supports its use in patients with coronary artery disease treated with ACE inhibitors.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/S0735-1097(99)00129-1</identifier><identifier>PMID: 10362194</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Science</publisher><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Aspirin - therapeutic use ; Biological and medical sciences ; Captopril - therapeutic use ; Coronary Disease - drug therapy ; Coronary Disease - mortality ; Cross-Over Studies ; Drug Interactions ; Drug Therapy, Combination ; Drug toxicity and drugs side effects treatment ; Enalapril - therapeutic use ; Female ; Heart Failure - drug therapy ; Heart Failure - mortality ; Humans ; Israel - epidemiology ; Male ; Medical sciences ; Middle Aged ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - therapeutic use ; Registries - statistics &amp; numerical data ; Risk Factors ; Survival Rate</subject><ispartof>Journal of the American College of Cardiology, 1999-06, Vol.33 (7), p.1920-1925</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1807224$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10362194$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LEOR, J</creatorcontrib><creatorcontrib>REICHER-REISS, H</creatorcontrib><creatorcontrib>GOLDBOURT, U</creatorcontrib><creatorcontrib>BOYKO, V</creatorcontrib><creatorcontrib>GOTTLIEB, S</creatorcontrib><creatorcontrib>BATTLER, A</creatorcontrib><creatorcontrib>BEHAR, S</creatorcontrib><title>Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors : A cohort study of 11,575 patients with coronary artery disease</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>The purpose of this study was to investigate the significance of the possible negative interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors. Several provocative reports have recently suggested that aspirin is unsafe in patients with heart failure and has negative interaction with ACE inhibitors that might attenuate their beneficial effects upon survival. We analyzed mortality data of 11,575 patients with coronary artery disease screened for the Bezafibrate Infarction Prevention trial. A total of 1,247 patients (11%) were treated with ACE inhibitors. Of them, 618 patients (50%) used aspirin. Five-year mortality was lower among patients on ACE inhibitors and aspirin than patients on ACE inhibitors without aspirin (19% vs. 27%; p &lt; 0.001). After adjusting for confounders, treatment with aspirin and ACE inhibitors remained associated with lower mortality risk than using ACE inhibitors only (relative risk [RR] = 0.71; 95% confidence interval [CI] = 0.56 to 0.91). Subgroup analysis of 464 patients with congestive heart failure treated with ACE inhibitors revealed 221 patients (48%) on aspirin and 243 patients not on aspirin. Although clinical characteristics and therapy were similar, patients taking aspirin experienced lower mortality than patients who did not (24% vs. 34%; p = 0.001). After adjustment, treatment with aspirin was still associated with lower mortality (RR = 0.70; 95% CI = 0.49 to 0.99). Among coronary artery disease patients with and without heart failure who are treated with ACE inhibitors, the use of aspirin was associated with lower mortality than treatment without aspirin. Our findings contradict the claim that aspirin attenuates the beneficial effect of ACE inhibitors and supports its use in patients with coronary artery disease treated with ACE inhibitors.</description><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Captopril - therapeutic use</subject><subject>Coronary Disease - drug therapy</subject><subject>Coronary Disease - mortality</subject><subject>Cross-Over Studies</subject><subject>Drug Interactions</subject><subject>Drug Therapy, Combination</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Enalapril - therapeutic use</subject><subject>Female</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - mortality</subject><subject>Humans</subject><subject>Israel - epidemiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Registries - statistics &amp; numerical data</subject><subject>Risk Factors</subject><subject>Survival Rate</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNpFkM1KAzEUhYMotv48gpKFCwVHcyfJJHFXin9QcKGuSyaT6UQ6mZKkyvgkPq6DVrs6cPnux-EgdALkCggU189EUJ4BUeJcqQtCIFcZ7KAxcC4zypXYReN_ZIQOYnwjhBQS1D4aAaFFDoqN0dckrlxwHmtf4bYLSS9d6vFwWOnkrE8Rp2B1shX-cKkZsIXrkvXR-cx0_t2G5PwCW__Zt3Z4a1zpUhcivsETbLpmMOKY1lWPuxoDXHLBt-Yfo-lC53XosQ7JDlG5aHW0R2iv1stojzd5iF7vbl-mD9ns6f5xOpllTS4gZcAl1bIivFCFEkBVrXIgRcUMKU3JpOECCs6YlDVnJZc1WM4JI1xQA4oW9BCd_npX67K11XwVXDu0mf9NNABnG0BHo5d10N64uOUkEXnO6DfSzXdh</recordid><startdate>19990601</startdate><enddate>19990601</enddate><creator>LEOR, J</creator><creator>REICHER-REISS, H</creator><creator>GOLDBOURT, U</creator><creator>BOYKO, V</creator><creator>GOTTLIEB, S</creator><creator>BATTLER, A</creator><creator>BEHAR, S</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19990601</creationdate><title>Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors : A cohort study of 11,575 patients with coronary artery disease</title><author>LEOR, J ; REICHER-REISS, H ; GOLDBOURT, U ; BOYKO, V ; GOTTLIEB, S ; BATTLER, A ; BEHAR, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h271t-1583a8d0569697139f92106d4c0bcb48c571654488f54b58f1e55040573c19363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Captopril - therapeutic use</topic><topic>Coronary Disease - drug therapy</topic><topic>Coronary Disease - mortality</topic><topic>Cross-Over Studies</topic><topic>Drug Interactions</topic><topic>Drug Therapy, Combination</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Enalapril - therapeutic use</topic><topic>Female</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - mortality</topic><topic>Humans</topic><topic>Israel - epidemiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Registries - statistics &amp; numerical data</topic><topic>Risk Factors</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LEOR, J</creatorcontrib><creatorcontrib>REICHER-REISS, H</creatorcontrib><creatorcontrib>GOLDBOURT, U</creatorcontrib><creatorcontrib>BOYKO, V</creatorcontrib><creatorcontrib>GOTTLIEB, S</creatorcontrib><creatorcontrib>BATTLER, A</creatorcontrib><creatorcontrib>BEHAR, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LEOR, J</au><au>REICHER-REISS, H</au><au>GOLDBOURT, U</au><au>BOYKO, V</au><au>GOTTLIEB, S</au><au>BATTLER, A</au><au>BEHAR, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors : A cohort study of 11,575 patients with coronary artery disease</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>1999-06-01</date><risdate>1999</risdate><volume>33</volume><issue>7</issue><spage>1920</spage><epage>1925</epage><pages>1920-1925</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>The purpose of this study was to investigate the significance of the possible negative interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors. Several provocative reports have recently suggested that aspirin is unsafe in patients with heart failure and has negative interaction with ACE inhibitors that might attenuate their beneficial effects upon survival. We analyzed mortality data of 11,575 patients with coronary artery disease screened for the Bezafibrate Infarction Prevention trial. A total of 1,247 patients (11%) were treated with ACE inhibitors. Of them, 618 patients (50%) used aspirin. Five-year mortality was lower among patients on ACE inhibitors and aspirin than patients on ACE inhibitors without aspirin (19% vs. 27%; p &lt; 0.001). After adjusting for confounders, treatment with aspirin and ACE inhibitors remained associated with lower mortality risk than using ACE inhibitors only (relative risk [RR] = 0.71; 95% confidence interval [CI] = 0.56 to 0.91). Subgroup analysis of 464 patients with congestive heart failure treated with ACE inhibitors revealed 221 patients (48%) on aspirin and 243 patients not on aspirin. Although clinical characteristics and therapy were similar, patients taking aspirin experienced lower mortality than patients who did not (24% vs. 34%; p = 0.001). After adjustment, treatment with aspirin was still associated with lower mortality (RR = 0.70; 95% CI = 0.49 to 0.99). Among coronary artery disease patients with and without heart failure who are treated with ACE inhibitors, the use of aspirin was associated with lower mortality than treatment without aspirin. Our findings contradict the claim that aspirin attenuates the beneficial effect of ACE inhibitors and supports its use in patients with coronary artery disease treated with ACE inhibitors.</abstract><cop>New York, NY</cop><pub>Elsevier Science</pub><pmid>10362194</pmid><doi>10.1016/S0735-1097(99)00129-1</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0735-1097
ispartof Journal of the American College of Cardiology, 1999-06, Vol.33 (7), p.1920-1925
issn 0735-1097
1558-3597
language eng
recordid cdi_pubmed_primary_10362194
source BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS
subjects Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Aspirin - therapeutic use
Biological and medical sciences
Captopril - therapeutic use
Coronary Disease - drug therapy
Coronary Disease - mortality
Cross-Over Studies
Drug Interactions
Drug Therapy, Combination
Drug toxicity and drugs side effects treatment
Enalapril - therapeutic use
Female
Heart Failure - drug therapy
Heart Failure - mortality
Humans
Israel - epidemiology
Male
Medical sciences
Middle Aged
Miscellaneous (drug allergy, mutagens, teratogens...)
Pharmacology. Drug treatments
Platelet Aggregation Inhibitors - therapeutic use
Registries - statistics & numerical data
Risk Factors
Survival Rate
title Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors : A cohort study of 11,575 patients with coronary artery disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A28%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aspirin%20and%20mortality%20in%20patients%20treated%20with%20angiotensin-converting%20enzyme%20inhibitors%20:%20A%20cohort%20study%20of%2011,575%20patients%20with%20coronary%20artery%20disease&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=LEOR,%20J&rft.date=1999-06-01&rft.volume=33&rft.issue=7&rft.spage=1920&rft.epage=1925&rft.pages=1920-1925&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/S0735-1097(99)00129-1&rft_dat=%3Cpubmed_pasca%3E10362194%3C/pubmed_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h271t-1583a8d0569697139f92106d4c0bcb48c571654488f54b58f1e55040573c19363%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/10362194&rfr_iscdi=true